Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $50.7100 (-2.5%) ($50.7100 - $50.7100) on Mon. Jan. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.26% (three month average) | RSI | 74 | Latest Price | $50.7100(-2.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(62%) ARKK(58%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.13% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.13% (StdDev 6.26%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $51.77(-2.05%) | 10 Day Moving Average | $52.87(-4.09%) | 20 Day Moving Average | $46.98(7.94%) | To recent high | -7.3% | To recent low | 101.1% | Market Cap | $6.422b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |